Drugs / INGAP Peptide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00034255 | Dec 2001 → ? | type 1 diabetes mellitus, type 2 diabetes mellitus | GMP Endotherapeutics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02204397 | Nov 2015 → Mar 2017 | type 1 diabetes mellitus | Jewish General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00071409 | Oct 2003 → May 2004 | type 1 diabetes mellitus | Exsulin Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00071422 | Oct 2003 → Jun 2004 | type 2 diabetes mellitus | Exsulin Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00995540 Comparator | Nov 2009 → Dec 2011 | type 1 diabetes mellitus | Exsulin Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INGAP Peptide | “300 mg INGAP Peptide” NCT00071422 ↗ |
| Action | Restore | “to restore the ability to produce insulin in type 1 diabetic patients” NCT00071409 ↗ |
| Modality | Peptide | “single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.” NCT00034255 ↗ |
| Route | Intramuscular | “intramuscular INGAP Peptide” NCT00034255 ↗ |